Company: NCEL
Filing Date: 2025-07-18
Form Type: 425
Source: 0001213900-25-065658
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: 425
Chunk 3
---
 the Company’s
Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which was filed with the SEC on May 16, 2025. Other information
regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or
otherwise, are contained in the F-4 Registration Statement and other relevant materials to be filed with the SEC regarding the proposed
transaction when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available
before making any voting or investment decisions. You may obtain free copies of these documents from the Company using the sources indicated
above.

<div align='center'>2

EXHIBIT INDEX</div>

<div align='center'>3

SIGNATURES</div>

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

| Date: July 18, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:--------------------|:-----------------------|:--------------------|:------------------------|
|                     |                        | Name:               | Alexander Zwyer         |
|                     |                        | Title:              | Chief Executive Officer |

<div align='center'>4</div>

Exhibit 99.1

<div align='center'>SIXTH AMENDMENT TO

AGREEMENT OF MERGER AND PLAN OF REORGANIZATION</div>

This Sixth Amendment to Agreement
of Merger and Plan of Reorganization (this “”) is made and entered into as of July 18, 2025, by and among
Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “”), NLS Pharmaceutics Ltd., a corporation
incorporated under the laws of Switzerland (“”), and NLS Pharmaceuticals (Israel) Ltd., an Israeli company (“”, and together with the Company and Parent, the “”). Capitalized terms used herein without definition
shall have the same definition ascribed thereto in the Agreement (as defined below).

WHEREAS, the Agreement
of Merger and Plan of Reorganization was made and entered into as of November 4, 2024, as amended as of January 30, 2025, as further amended
as of February 17, 2025, as